Dexcom (DXCM) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $994.2 million, with 3% organic growth, driven by international expansion, new product launches, and record new patient starts, while U.S. sales stabilized but declined due to channel mix and rebates.

• Stelo, the first OTC glucose biosensor in the U.S., launched with strong early adoption, targeting prediabetes and Type 2 diabetes, and expanded Dexcom ONE+ to 19 countries.

• Chief Commercial Officer retirement announced, with CEO assuming interim commercial leadership.

• $750 million share repurchase program completed, reflecting strong capital allocation.

• Ended Q3 with $2.5 billion in cash, cash equivalents, and marketable securities.

Financial highlights

• Q3 2024 worldwide revenue was $994.2 million, up 2% reported and 3% organic year-over-year.

• U.S. revenue declined 2% to $701.9 million, while international revenue grew 12% to $292.3 million.

• Non-GAAP gross profit was $625.9 million (63% margin); GAAP gross margin was 59.7%, impacted by a $24.6 million non-cash inventory charge.

• Non-GAAP operating income was $212 million (21.3% margin), and adjusted EBITDA was $300.1 million (30.2% margin); net income was $179.9 million ($0.45 per share non-GAAP, $0.34 GAAP).

• Operating cash flow for the first nine months was $688.1 million, up from $614.9 million in the prior year.

Outlook and guidance

• 2024 revenue guidance reaffirmed at $4.0–$4.05 billion (11–13% organic growth), with margin targets of ~63% gross, ~20% operating, and ~29% adjusted EBITDA.

• 2025 long-range plan targets $4.6 billion revenue and margin improvements, including contributions from Stelo and new launches.

• Management expects continued positive operating cash flows and sufficient liquidity for at least the next 12 months.